Cellosaurus cell line LNCaP C4-2B (CVCL

Cellosaurus LNCaP C4-2B (CVCL_4784)

[Text version]

Cell line name

LNCaP C4-2B

Synonyms

C4-2B; C4-2 B; C4-2 Bone metastatic

Accession

CVCL_4784

Resource Identification Initiative

To cite this cell line use: LNCaP C4-2B (RRID:CVCL_4784)

Comments

Population: Caucasian.
Characteristics: Bone metastatic.
Doubling time: ~24-36 hours (ATCC=CRL-3315).
Omics: Deep exome analysis.
Omics: Transcriptome analysis by RNAseq.
Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.

Sequence variations

Mutation; HGNC; HGNC:644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).

Disease

Prostate carcinoma (NCIt: C4863)

Species of origin

Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy

Parent: CVCL_4782 (LNCaP C4-2)
Children:

CVCL_4785 (LNCaP C4-2B2)	CVCL_4786 (LNCaP C4-2B3)	CVCL_4787 (LNCaP C4-2B4)
CVCL_4788 (LNCaP C4-2B5)	CVCL_D8FB (Ubigene C4-2B MRPL40 KO)

Sex of cell

Male

Age at sampling

50Y

Category

Cancer cell line

STR profile

Source(s): ATCC=CRL-3315

Markers:

Amelogenin	X,Y
CSF1PO	9,10,11
D5S818	11,12
D7S820	8.1,9.1,10.3
D13S317	10,11
D16S539	10,11
TH01	9
TPOX	8,9
vWA	16,18

Web pages

https://en.wikipedia.org/wiki/LNCaP

Publications

PubMed=8168083
Thalmann G.N., Anezinis P.E., Chang S.-M., Zhau H.-Y.E., Kim E.E., Hopwood V.L., Pathak S., von Eschenbach A.C., Chung L.W.K.
Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
Cancer Res. 54:2577-2581(1994)

PubMed=15162376; DOI=10.1002/pros.20031
Liu A.Y., Brubaker K.D., Goo Y.A., Quinn J.E., Kral S., Sorensen C.M., Vessella R.L., Belldegrun A.S., Hood L.E.
Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines.
Prostate 60:98-108(2004)

PubMed=24587179; DOI=10.1371/journal.pone.0090002; PMCID=PMC3938550
Spans L., Helsen C., Clinckemalie L., Van den Broeck T., Prekovic S., Joniau S., Lerut E., Claessens F.
Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines.
PLoS ONE 9:E90002-E90002(2014)

PubMed=33298586; DOI=10.1158/1535-7163.MCT-20-0244; PMCID=PMC7867613
Kohrt S.E., Awadallah W.N., Phillips R.A. 3rd, Case T.C., Jin R.-J., Nanda J.S., Yu X.-P., Clark P.E., Yi Y.-J., Matusik R.J., Anderson P.D., Grabowska M.M.
Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells in vitro.
Mol. Cancer Ther. 20:398-409(2021)

PubMed=35502546; DOI=10.1158/0008-5472.CAN-22-1065; PMCID=PMC9153264
Abate-Shen C., Nunes de Almeida F.
Establishment of the LNCaP cell line -- the dawn of an era for prostate cancer research.
Cancer Res. 82:1689-1691(2022)

Cross-references

Cell line collections (Providers)

ATCC; CRL-3315

Cell line databases/resources

cancercelllines; CVCL_4784

Anatomy/cell type resources

BTO; BTO_0004959

Biological sample resources